We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Moderna is expected to beat Q4 estimates, with sales projected at $661.4M and a loss of $2.60 per share.
COVID-19 vaccines are expected to drive most sales, while the RSV vaccine mResvia faces tough competition.
Investors await updates on intismeran studies and FDA resubmission plans for the COVID-flu combo vaccine.
We expect Moderna (MRNA - Free Report) to surpass expectations when it reports fourth-quarter and full-year 2025 results on Feb. 13, before the opening bell. The company’s earnings beat estimates by 76.28% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $661.4 million and a loss of $2.60 per share, respectively.
Factors Shaping Moderna’s Upcoming Results
Moderna currently has three marketed products in its portfolio — two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia). The Zacks Consensus Estimate for overall product sales is pegged at $627 million, with a significant portion coming from the COVID-19 vaccines.
We expect minimal product sales of the company's RSV vaccine, mResvia. Thissofter sales expectation is likely due to stiff competition and the strong foothold of the competing RSV vaccines marketed by GSK and Pfizer.
Moderna is developing more than 30 mRNA-based investigational candidates across different stages of clinical studies, targeting various indications, including cancer. Investors will likely focus on updates surrounding pipeline development.
An important candidate in Moderna’s pipeline is intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK - Free Report) . Last month, the companies reported encouraging median five-year follow-up data from a mid-stage study, which evaluated the therapy plus Merck’s blockbuster oncology drug Keytruda in certain patients with high-risk melanoma. The combo therapy reduced the risk of recurrence or death by 49% versus Keytruda alone in patients with high-risk melanoma following complete resection.
Moderna and Merck are currently evaluating intismeran in three pivotal phase III studies — one in the melanoma indication and the other two in the non-small cell lung cancer space. It is also being evaluated in separate mid-stage studies across other cancer indications, such as bladder cancer and renal carcinoma. Investors will likely be seeking updates from management on this Merck-partnered therapy’s progress across these studies.
Investors’ attention will also be on mRNA-1083, Moderna’s COVID-19/influenza combination vaccine, which remains on track for FDA resubmission soon. The initial filing was voluntarily withdrawn last year after the agency requested additional efficacy data for the flu component. This issue was addressed with positive late-stage data announced in June, where the company’s standalone flu shot, mRNA-1010, demonstrated superior efficacy compared with GSK’s approved influenza vaccine. mRNA-1083 integrates the company’s COVID-19 vaccine with mRNA-1010.
MRNA’s Earnings Surprise History
The firm’s performance has been impressive over the past four quarters. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 31.45%.
In the past year, Moderna’s shares have risen nearly 29% compared with the industry’s 39% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for MRNA
Our proven model predicts an earnings beat for Moderna this time around. The combinationofa positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Moderna has an Earnings ESP of +3.16%. The Most Accurate Estimate stands at a loss of $2.52 per share, while the Zacks Consensus Estimate is pegged at a loss of $2.60.
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +68.89% and a Zacks Rank #1 at present.
Shares of CSTL have risen 18% in the past year. The company’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. Castle Biosciences delivered an average surprise of 66.11%. It is scheduled to report Q4 results on Feb. 26.
Jazz Pharmaceuticals (JAZZ - Free Report) has an Earnings ESP of +5.45% and a Zacks Rank #3 at present.
Shares of JAZZ have risen 34% in the past year. The company’s earnings beat estimates in two of the trailing four quarters while missing the mark on the other two occasions, delivering a negative average surprise of 10.48%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?
Key Takeaways
We expect Moderna (MRNA - Free Report) to surpass expectations when it reports fourth-quarter and full-year 2025 results on Feb. 13, before the opening bell. The company’s earnings beat estimates by 76.28% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $661.4 million and a loss of $2.60 per share, respectively.
Factors Shaping Moderna’s Upcoming Results
Moderna currently has three marketed products in its portfolio — two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia). The Zacks Consensus Estimate for overall product sales is pegged at $627 million, with a significant portion coming from the COVID-19 vaccines.
We expect minimal product sales of the company's RSV vaccine, mResvia. Thissofter sales expectation is likely due to stiff competition and the strong foothold of the competing RSV vaccines marketed by GSK and Pfizer.
Moderna is developing more than 30 mRNA-based investigational candidates across different stages of clinical studies, targeting various indications, including cancer. Investors will likely focus on updates surrounding pipeline development.
An important candidate in Moderna’s pipeline is intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK - Free Report) . Last month, the companies reported encouraging median five-year follow-up data from a mid-stage study, which evaluated the therapy plus Merck’s blockbuster oncology drug Keytruda in certain patients with high-risk melanoma. The combo therapy reduced the risk of recurrence or death by 49% versus Keytruda alone in patients with high-risk melanoma following complete resection.
Moderna and Merck are currently evaluating intismeran in three pivotal phase III studies — one in the melanoma indication and the other two in the non-small cell lung cancer space. It is also being evaluated in separate mid-stage studies across other cancer indications, such as bladder cancer and renal carcinoma. Investors will likely be seeking updates from management on this Merck-partnered therapy’s progress across these studies.
Investors’ attention will also be on mRNA-1083, Moderna’s COVID-19/influenza combination vaccine, which remains on track for FDA resubmission soon. The initial filing was voluntarily withdrawn last year after the agency requested additional efficacy data for the flu component. This issue was addressed with positive late-stage data announced in June, where the company’s standalone flu shot, mRNA-1010, demonstrated superior efficacy compared with GSK’s approved influenza vaccine. mRNA-1083 integrates the company’s COVID-19 vaccine with mRNA-1010.
MRNA’s Earnings Surprise History
The firm’s performance has been impressive over the past four quarters. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 31.45%.
Moderna, Inc. Price and EPS Surprise
Moderna, Inc. price-eps-surprise | Moderna, Inc. Quote
Moderna’s Stock Movement
In the past year, Moderna’s shares have risen nearly 29% compared with the industry’s 39% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for MRNA
Our proven model predicts an earnings beat for Moderna this time around. The combinationofa positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Moderna has an Earnings ESP of +3.16%. The Most Accurate Estimate stands at a loss of $2.52 per share, while the Zacks Consensus Estimate is pegged at a loss of $2.60.
Zacks Rank: MRNA currently carriesa Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks With Favorable Combinations
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +68.89% and a Zacks Rank #1 at present.
Shares of CSTL have risen 18% in the past year. The company’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. Castle Biosciences delivered an average surprise of 66.11%. It is scheduled to report Q4 results on Feb. 26.
Jazz Pharmaceuticals (JAZZ - Free Report) has an Earnings ESP of +5.45% and a Zacks Rank #3 at present.
Shares of JAZZ have risen 34% in the past year. The company’s earnings beat estimates in two of the trailing four quarters while missing the mark on the other two occasions, delivering a negative average surprise of 10.48%.